Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H U Group HoldingsMRCHF -0.18%63 3-Year ROIIC % is 40.01 as of Mar. 2026, which is at its 10-year median of 40.01. GuruFocus rates MRCHF with a GF Score™ of 63/100 and a GF Value™ of $19.09 (Fairly Valued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, H U Group Holdings ranks better than 72.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
H U Group Holdings's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 40.01%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for H U Group Holdings's 3-Year ROIIC % or its related term are showing as below:
MRCHF's 3-Year ROIIC % is ranked better than 72.55% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs MRCHF: 40.01
H U Group Holdings (OTCPK:MRCHF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
H U Group Holdings 3-Year ROIIC % Related Terms
H U Group Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for H U Group Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRCHF vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, H U Group Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H U Group Holdings 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, H U Group Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where H U Group Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
H U Group Holdings (MRCHF) has a 3-Year ROIIC % of 40.01 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on H U Group Holdings and its competitors. This is near median its historical median of 40.01. According to the industry distribution chart, H U Group Holdings ranks #56 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 27.5%.
Is H U Group Holdings' 3-Year ROIIC % too high?
H U Group Holdings' current 3-Year ROIIC % of 40.01 is near median its 10-year median of 40.01. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.13. H U Group Holdings' value of 40.01 is 31908% above this industry median. Based on the distribution chart, H U Group Holdings ranks #56 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, H U Group Holdings has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H U Group Holdings' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, H U Group Holdings ranks #56 out of 204 companies for 3-Year ROIIC %. This puts H U Group Holdings in the upper half of its industry. The industry median 3-Year ROIIC % is 0.13. H U Group Holdings' value of 40.01 is 31908% above this benchmark. While the company's 10-year median is 40.01 vs. the industry median of 0.13, H U Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H U Group Holdings's current 3-Year ROIIC % of 40.01 is 31908% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on H U Group Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H U Group Holdings's current 3-Year ROIIC % is 40.01, which is near median its own 10-year median of 40.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H U Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, H U Group Holdings (MRCHF) is currently considered Fairly Valued. The stock's GF Value™ is $19.09, compared to a current price of $20.90 — trading 9.5% above its estimated fair value. The current 3-Year ROIIC % is 40.01, which is near median its 10-year median of 40.01 and 31908% above the Medical Diagnostics & Research industry median of 0.13. H U Group Holdings' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For H U Group Holdings (MRCHF), the current 3-Year ROIIC % is 40.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H U Group Holdings (MRCHF) Overvalued in 2026?
Based on GuruFocus' analysis, H U Group Holdings stock appears to be overvalued.
The current stock price of $20.90 is trading 9.5% above its estimated GF Value™ of $19.09.
GuruFocus considers H U Group Holdings to be Fairly Valued.
Key valuation signals for MRCHF:
3-Year ROIIC %: 40.01 (near median its 10-year median of 40.01)
GF Value™: $19.09 vs. price of $20.90 (9.5% above fair value)
Industry Position: 31908% above the Medical Diagnostics & Research median (#56 of 204)
No single metric tells the full story. See the MRCHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
H U Group Holdings Inc operates in the healthcare field, focusing on clinical laboratory testing and reagents. The company is engaged in four main businesses. The Clinical Laboratory Testing Business receives samples taken from patients at medical institutions to test for the disease and confirm the condition of the patient's health; In Vitro Diagnostics develops, manufactures, and sells testing reagents and equipment inside and outside Japan; Sterilization & Related Services Business provides a range of medical-related services including sterilization; and Emerging New Business & Others is a new business for future growth.
63GF Score
Get the complete analysis for MRCHF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRCHF has been successfully added to your 
